News
VALN
5.66
-1.74%
-0.10
Valneva Reports Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate
TipRanks · 8h ago
Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ
NASDAQ · 3d ago
Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups
Benzinga · 3d ago
Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies
Benzinga · 4d ago
Valneva’s Lyme Vaccine Catalysts Support Buy Rating and Significant Upside
TipRanks · 4d ago
Weekly Report: what happened at VALN last week (1102-1106)?
Weekly Report · 4d ago
Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2
NASDAQ · 4d ago
Valneva Announces November 24 Release of Nine-Month 2026 Results
TipRanks · 11/06 15:27
Weekly Report: what happened at VALN last week (1026-1030)?
Weekly Report · 11/02 10:24
Weekly Report: what happened at VALN last week (1019-1023)?
Weekly Report · 10/26 10:23
Weekly Report: what happened at VALN last week (1012-1016)?
Weekly Report · 10/19 10:23
Full Transcript: Valneva Q2 2026 Earnings Call
Benzinga · 10/14 10:05
Weekly Report: what happened at VALN last week (1005-1009)?
Weekly Report · 10/12 10:29
UK Revokes Approval for Valneva's Chikungunya Shot
Benzinga · 10/08 18:27
Biggest stock movers Thursday: MRVL, APLD, and more
Seeking Alpha · 10/08 09:01
UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide
NASDAQ · 10/08 06:47
Valneva falls as UK revokes marketing authorization for chikungunya vaccine
Seeking Alpha · 10/07 21:41
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/07 21:06
Valneva announces Ixchiq marketing authorization revoked by UK MHRA
TipRanks · 10/07 20:15
Weekly Report: what happened at VALN last week (0928-1002)?
Weekly Report · 10/05 10:29
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.